Medytox secured Colombian regulatory approval for three hyaluronic acid fillers, extending its footprint in Latin America and signaling the company's strategy to compete beyond botulinum toxin. Medytox has been aggressive in building a full-line aesthetic portfolio to compete with AbbVie and Galderma in markets where it lacks historical dominance.
Regulatory
Medytox Wins Colombian Approval for Three HA Fillers
South Korean toxin maker expands filler portfolio in Latin America.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Medytox expands beyond toxin to build a full aesthetic portfolio.
For U.S. practices, this is a longer-term watch. Medytox's toxin (Meditoxin) remains available in select U.S. markets through limited channels, but the company has not yet secured broad FDA clearance for a filler line. The Colombian approval demonstrates regulatory capability and manufacturing scale. If Medytox enters the U.S. filler market—either directly or through a partner—it would add competitive pressure to Restylane and Juvéderm pricing.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.